StockNews.com Upgrades USANA Health Sciences (NYSE:USNA) to Strong-Buy

StockNews.com upgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a strong-buy rating in a research note published on Thursday.

Separately, DA Davidson reduced their price objective on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday, October 23rd.

USANA Health Sciences Price Performance

USNA stock opened at $33.38 on Thursday. USANA Health Sciences has a 1 year low of $33.28 and a 1 year high of $54.81. The stock has a market cap of $636.22 million, a price-to-earnings ratio of 11.80, a P/E/G ratio of 1.25 and a beta of 0.89. The company has a 50 day simple moving average of $37.91 and a 200 day simple moving average of $40.37.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The company had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same period in the prior year, the firm posted $0.59 EPS. On average, equities research analysts anticipate that USANA Health Sciences will post 2.45 EPS for the current fiscal year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Safe Harbor Fiduciary LLC purchased a new position in shares of USANA Health Sciences during the 3rd quarter valued at $30,000. KBC Group NV raised its holdings in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after acquiring an additional 519 shares during the period. BOKF NA lifted its position in shares of USANA Health Sciences by 99.4% in the second quarter. BOKF NA now owns 5,526 shares of the company’s stock valued at $250,000 after acquiring an additional 2,755 shares in the last quarter. Centiva Capital LP bought a new position in shares of USANA Health Sciences in the third quarter worth about $213,000. Finally, Quest Partners LLC purchased a new stake in shares of USANA Health Sciences during the third quarter worth about $250,000. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.